Advancements in the Treatment of Glioblastoma: "More Drug is Not Always Better"

In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Nader Sanai, MD. Dr. Sanai is the director of the Ivy Brain Tumor Center and the director of neurosurgical oncology at the Barrow Neurological Institute in Phoenix, Arizona. In this episode of the program Hofland asked Sanai about Phase 0 studies – also known as micro-dosing studies – and why they are so important in the development of promising new drugs. They also talk about a potential, non-invasive treatment option for glioblastoma as well as and data he presented during the annual meeting of the European Society for Medical Oncology the meeting of the European Association for Neuro-Oncology. About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.